Two decades after BRCA: setting paradigms in personalized cancer care and prevention
about
Breast cancer risk factorsUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicIdentification et prise en charge des femmes ayant des antécédents familiaux de cancer du sein: Guide pratique à l’intention des médecinsIdentification and management of women with a family history of breast cancer: Practical guide for cliniciansMolecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancerGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesProbing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1Pioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical ScienceRecO protein initiates DNA recombination and strand annealing through two alternative DNA binding mechanisms.Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistanceValidation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Lobular breast cancer: incidence and genetic and non-genetic risk factors.Comprehensive analysis of pathogenic deletion variants in Fanconi anemia genes.Functional consequence of the MET-T1010I polymorphism in breast cancerNew recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencingQ&A: insulin secretion and type 2 diabetes: why do β-cells fail?Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors.Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countriesEpigenetic changes in BRCA1-mutated familial breast cancerEthnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization.Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study.Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer.The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from UkraineTumor characteristics and prognosis in familial breast cancer.Availability and payer coverage of BRCA1/2 tests and gene panels.Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypesBiopsychosocial influence on shoulder pain: risk subgroups translated across preclinical and clinical prospective cohorts.Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutationEpigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution.Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.Discriminatory power of common genetic variants in personalized breast cancer diagnosis.Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic targetHaplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancerProteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples.Long non-coding RNAs as prognostic markers in human breast cancer.
P2860
Q26777289-94F7CF50-5AF9-4734-831F-EFF0733C72FEQ28071541-C328AA10-A904-4E04-8EFF-DDD905FCDD05Q28077316-78A7A46F-50EB-4CCF-AB7D-AE6CB5547783Q28077578-B700356B-2514-4972-AE68-D627BBC759A6Q28088790-DC0F9304-D068-48A5-AC3C-B67CD5C5DE0CQ28388497-22280676-4C23-4ACB-A29F-6D3E78E113A6Q28539000-7ACB29D2-D45E-4FF9-8D79-27FCCCEB555FQ28654820-13E06966-BEC0-489C-B4AE-4424FFB6508BQ30366224-99F5C554-C9DE-4517-A838-9E00CE6F8F08Q33677756-12D7E900-1CE7-461F-AF05-BF1CF3A067A9Q33688407-26B5CD16-469E-411A-9502-D57C7D83949FQ33751777-F411460E-B551-4694-B9FE-7090594AE0B3Q33798999-73AFC32D-AE7B-41E1-BE08-9E649B411BD8Q35170028-5B52EDD0-C9F1-4101-9497-9FABF965D22DQ35532131-3886DE30-E292-4F05-9C07-A4E98688EB3DQ35550045-33E3F54B-EC89-407F-BB35-BAEFAC5C0936Q35600785-678AA20A-609E-4F86-ACD4-BDF0EC83D43EQ35619020-E6BD063C-99FB-48C2-9796-2572F2166F62Q35673016-55A074DE-075A-4FCF-A739-F034D081A384Q35695425-4157EC0F-A2CE-4066-B140-7DB3C53156CCQ35738660-C617D411-5A66-46E9-ADD4-BDD7B47C6859Q35999539-DC3566ED-A2D5-4FCB-9290-6BEE63991AC8Q36031290-34841775-5AA0-44CC-BB1F-D0C87BA92B1CQ36098650-9883D646-78D3-4D0A-A7DA-1882EF09C774Q36098651-72B331A8-BB46-41A2-B586-DB08687949E7Q36161162-49BC9906-AEE7-43AA-BC5E-E5A6DBC1F497Q36207051-BE6CEBDB-F187-4490-B840-F5FF516FC2E2Q36224136-744B6018-419F-43DB-88A1-8CFAD6FAFC46Q36252996-19098A60-106A-414E-B8CF-63CE89FC3D73Q36289931-8DA9EE56-2CC2-4B0D-AC11-8EAE7E5B7783Q36413155-A28D9CC8-CAE2-4A35-B073-B7CEB2035EC1Q36710202-E15C64B2-D142-4A03-8DB7-BFD8964478B8Q36907261-FFEF0280-2F06-4039-B2D8-5289B0FF1DBBQ36959885-6E241BB1-8D61-4A7C-A6FE-7A45A8896818Q36962696-FC539C2D-D1CD-444B-A741-15EDA036E24BQ36972302-6CC369FF-DDE5-41A6-B660-7F6494FA5C4FQ36990060-0FEA2239-090D-418C-9B91-86406442E2C7Q37032901-091886B0-BD70-414C-8E81-703CF54BB5CAQ37054767-5431D80C-0664-4466-AFCB-4750A6696A90Q37190379-C44B8AD8-A391-49E4-BC8B-037EB7369323
P2860
Two decades after BRCA: setting paradigms in personalized cancer care and prevention
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Two decades after BRCA: setting paradigms in personalized cancer care and prevention
@ast
Two decades after BRCA: setting paradigms in personalized cancer care and prevention
@en
type
label
Two decades after BRCA: setting paradigms in personalized cancer care and prevention
@ast
Two decades after BRCA: setting paradigms in personalized cancer care and prevention
@en
prefLabel
Two decades after BRCA: setting paradigms in personalized cancer care and prevention
@ast
Two decades after BRCA: setting paradigms in personalized cancer care and prevention
@en
P2860
P50
P356
P1433
P1476
Two decades after BRCA: setting paradigms in personalized cancer care and prevention
@en
P2860
P304
P356
10.1126/SCIENCE.1251827
P407
P577
2014-03-01T00:00:00Z